Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Animals Data Shows Drug Can Protect Against Marburg 72 Hours after Infection


Tekmira Pharmaceuticals this week announced the release of new preclinical data showing that the company's RNAi-based Marburg virus drug could prevent death in non-human primates infected with a lethal dose of the pathogen.

The animals were infected with the virus, then given 0.5 mg/kg doses of the drug — TKM-Marburg — once a day for seven days 72 hours later. All of the treated primates survived.

Previously, Tekmira and collaborators at the University of Texas Medical Branch showed that TKM-Marburg could offer complete protection from lethal Marburg infection when given 24 hours and 48 hours after exposure.

In a presentation at the 6th International Symposium of Filoviruses this week, Tekmira Chief Technology Officer Ian MacLachlan said that forthcoming studies will test TKM-Marburg's efficacy in non-human primates 96 hours after Marburg infection.

Tekmira currently has a treatment for another filovirus, Ebola, in Phase I development. As reported by Gene Silencing News, the company recently received a National Institutes of Health grant to develop a single RNAi agent against both Ebola and Marburg viruses.